Delivery Order SPE2DB24D2018-SPE2DB26FWRN4
- Not listed
- The Defense Logistics Agency awarded a $11,830 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body injector units on July 29, 2025, with an ultimate completion date of August 19, 2025. This firm fixed price delivery order, which was competitively awarded with no set-aside designation, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a prescription biologic medication used to treat autoimmune conditions, and...
- The Defense Logistics Agency awarded a $25,209.26 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body injectors on April 29, 2025, with a completion date of May 20, 2025. This firm fixed price, non-set-aside contract was issued under a competitive procurement process and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic treatment used for dermatological conditions, representing part of the company's...
- The Defense Logistics Agency awarded a delivery order valued at $12,467.00 to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 ml on-body injectable medication. This is a firm fixed-price, non-set-aside contract awarded on October 27, 2025, with a completion deadline of November 18, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 ml on-body injector units, with a completion deadline of June 23, 2025. This non-competitive delivery order was awarded on May 30, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic medication used to treat inflammatory skin conditions, and this order represents a routine...
- The Defense Logistics Agency awarded a $12,467 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 mg/2.4 mL on-body injectors on October 24, 2025. This competitively awarded, firm fixed-price contract, which carries no set-aside designation, is scheduled for completion by November 17, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. SKYRIZI is a specialized biologic medication indicated for inflammatory skin conditions,...
- The Defense Logistics Agency awarded a $12,467.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for SKYRIZI 360 MG/2.4 ML on-body 2.4ML injectable medication on October 22, 2025, with completion targeted for November 13, 2025. This non-set-aside delivery order will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's broader pharmaceutical supply relationship with the Defense Logistics Agency,...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of SKYRIZI 360 mg/2.4 ml on-body injectors. The contract, which carries an ultimate completion date of September 29, 2025, represents a non-set-aside competitive award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectable medication. This competitive award, issued on September 18, 2025, represents a firm fixed price delivery order with an ultimate completion date of October 9, 2025. The contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. SKYRIZI is a biologic...
- The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of SKYRIZI 360 mg/2.4 mL on-body injectors. The order, with an ultimate completion date of September 5, 2025, represents a non-set-aside competitive award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. SKYRIZI is a biologic immunosuppressant used in the treatment of plaque psoriasis and other inflammatory conditions,...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $11,830.00 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectable medication. This firm fixed-price, non-set-aside contract was awarded on July 28, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- SPE2DB24D2018Indefinite Delivery Contract
- SPE2DB24D2018-SPE2DB26FWRN4Delivery Order
The Defense Logistics Agency awarded a $11,830 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injectable medication in 2.4 mL quantities. The award, issued on October 27, 2025, with an ultimate completion date of November 18, 2025, was made without a set-aside designation through competitive procurement. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and primary distribution center. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications, vaccines, and medical supplies to support military and veteran healthcare systems worldwide. SKYRIZI, a biologic treatment for inflammatory conditions, exemplifies the specialized pharmaceutical products the company delivers through its federal contract portfolio, which encompasses both brand-name and generic medications across multiple therapeutic domains serving the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 10/27/25 |